Please assess the completion status of the following clinical trial:

Trial Title: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Definite or probable CIDP according to the European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) criteria 2010.~* An IVIG treatment during the last 8 weeks prior to enrollment.~* Age ≥18 years.~* Written informed consent for study participation obtained before undergoing any study-specific procedures.~Exclusion Criteria:~* Any polyneuropathy of other causes~* Any other disease (mainly neurological or chronic orthopedic) that has caused neurological symptoms or may interfere with treatment or outcome assessments~* Severe diseases and conditions that are likely to interfere with evaluation of the study product or satisfactory conduct of the study~* History of thrombotic episodes within the 2 years prior to enrolment~* Known allergic or other severe reactions to blood products including intolerability to previous IVIG

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IgPro20 low dose (Type: EXPERIMENTAL): None
- IgPro20 high dose (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).